Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C
Sponsor: ANRS, Emerging Infectious Diseases
Summary
The purpose of this study is to examine the efficacy of irbesartan on the progression of liver fibrosis in adult patients with chronic hepatitis C. The expected total enrollment is 200 patients. Patients who meet the study criteria and accept to participate at this study will take by day one tablet of 150 mg of treatment (irbesartan or placebo) during two years. The assessment of efficacy will be make by evaluation of area of liver fibrosis and blood markers of liver fibrosis
Official title: Study of the Effects of a Sartan on Hepatic Fibrosis Progression in Chronic Viral Hepatitis C
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
166
Start Date
2006-10
Completion Date
2013-11
Last Updated
2026-04-13
Healthy Volunteers
No
Conditions
Interventions
Irbesartan
one tablet of 150 mg/d during 2 years
placebo
one tablet per day during 2 years
Locations (1)
CHU Angers, Service d'hépato-gastroentérologie
Angers, France